Modified Alpha-Hemolysin Vaccine Composition Against Pre-Existing Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine efforts against Staphylococcus aureus infection have failed to induce a protective immune response and are hindered by pre-existing immunity, necessitating a novel approach grounded in understanding human immunity to this pathogen.
Innovation Solution
Development of a modified α-hemolysin (Hla) polypeptide with specific amino acid substitutions (H35L, R66C, and E70C) to enhance germinal center and T follicular helper cell responses, inducing robust immune protection against Staphylococcus aureus.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If vaccine candidates are developed to induce immune response against S. aureus, then immunogenicity is improved, but pre-existing immunity worsens vaccine efficacy
Solution Approach 1:
The patent applies parameter changes by modifying specific amino acid residues in the Hla toxin structure (positions 35, 66, and 70) to create mutant variants with altered immunogenic properties. These structural parameter changes enable the vaccine to induce a different type of immune response that overcomes the blocking effect of pre-existing immunity while maintaining high immunogenicity
Solution Approach 2:
The patent converts the harmful effect of pre-existing immunity into a benefit by designing vaccine candidates that specifically target germinal center and T follicular helper cell responses. This approach transforms the situation where pre-existing immunity normally blocks vaccine efficacy into an opportunity to induce a more robust and protective immune response type
2Reliability
If modified Hla polypeptide with multiple amino acid substitutions is used, then germinal center and T follicular helper cell responses are enhanced, but manufacturing complexity increases
Solution Approach 1:
The patent systematically changes specific parameter points (amino acid positions) in the Hla polypeptide structure to achieve the desired immune response enhancement while maintaining overall structural integrity and manufacturability
Solution Approach 2:
The patent applies local quality changes by modifying only specific localized regions (three particular amino acid positions) of the Hla polypeptide rather than altering the entire structure. This localized approach achieves enhanced immune responses while minimizing manufacturing complexity
Data Source
AI summary
Provided herein are compositions and methods for the treatment of Staphylococcus aureus.